March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Research reveals significant associations between environmental microplastic pollution and increased rates of hypertension, diabetes, and stroke across U.S. coastal communities, with pollution levels ranking among top predictors for chronic disease prevalence.
"Partial weight regain after substantial weight loss was associated with a less favorable cardiovascular risk profile and an increased incidence of both microvascular and macrovascular diseases."